South County Health becomes the first health system in Rhode Island to join the Mayo Clinic Care Network, gaining access to Mayo Clinic's knowledge and resources. This partnership enables South County Health clinicians to consult Mayo Clinic expertise when needed, supporting high-quality care in the community.
Mayo Clinic researchers report encouraging early results from an experimental therapy targeting the genetic cause of a rare form of ALS. The single-patient study identified a mutation in CHCHD10, which appears to make the CHCHD10 protein harmful to nerve cells and is linked to abnormal changes in TDP-43.
Researchers found distinct gut microbiome patterns in adults 50 or younger with colorectal and breast cancers compared to those diagnosed later in life. The study identified broad microbiome differences between cancer patients and healthy individuals, and pinpointed specific bacterial species associated with five cancer groups.
A multicenter study found that fractionated stereotactic radiosurgery reduced brain metastases recurrence and improved survival rates compared to single treatment. The approach delivered higher total doses and allowed healthy tissue to recover between treatments, while tumor cells couldn't repair.
Mayo Clinic researchers will present emerging technologies, precision treatments, and new radiation therapy techniques at ASTRO 2026. The meeting highlights include presentations on AI-driven automation in pelvic radiation therapy and novel therapies for glioblastoma.
A large prospective study found that a multicancer blood test identified cancer signals across 17 broad cancer types, including ovarian, lung, and breast cancers. The test correctly predicted cancer diagnoses in 60.3% of cases, with 99.64% specificity.
Mayo Clinic and Helix partner to generate clinical whole genome sequencing and multi-omics data from one million biospecimens, accelerating precision medicine. The partnership aims to integrate molecular insights into routine clinical care, detecting disease sooner and acting earlier.
Researchers have identified a strategy to reprogram aggressive thyroid cancer cells to make them visible to CAR-T cells, leading to better tumor control and survival. The approach involves using drugs to restore a marker on thyroid cancer cells, making them more vulnerable to CAR-T cell attack.
Mayo Clinic researchers report encouraging results using minibeam radiotherapy, delivering high doses of radiation to treat resistant cancers near the skin. The technique improved symptoms in 86% of patients and showed tumor regression and stability in 45% and 25% of tumors respectively.
Precure, LLC creates one of the world's leading biomedical datasets by integrating proteomic, genomic, and longitudinal clinical data, helping researchers identify early biological signals of disease. This data will accelerate drug development and enable more precise therapies across various diseases.
The Mayo Clinic Care Network has grown to include 80 hospitals and 20,000 physicians, with member organizations accessing Mayo Clinic's clinical knowledge and specialists while maintaining local patient care. The network has supported advancements in healthcare through knowledge sharing, data-driven innovation, and emerging technologies.
Researchers found that spatial patterns in pathology slides can identify patients at greater risk of pancreatic cancer recurrence after treatment. AI-enabled analysis measured tissue shape, fragmentation, and cancer-stroma intermixing to predict disease-free survival.
Mayo Clinic researchers have identified a potential new approach to treating glioblastoma by reprogramming immune cells and boosting chemotherapy response. Inhibiting the enzymatic activity of MALT1 protein can shift immune cells from a protective state to one that promotes an antitumor immune response.
The 12 companies selected will work alongside Mayo Clinic Platform's experts and leverage its de-identified clinical data ecosystem to advance digital health solution development. The program aims to transform healthcare through AI-enabled solutions leveraging clinical data and advanced analytics.
A new AI-assisted approach uses artificial intelligence to help novice users capture heart images and identify patients with aortic stenosis. The approach, presented in a study published in JAMA Cardiology, enables novice users to collect focused heart ultrasound images and analyze them for signs of moderate or greater aortic stenosis,...
Researchers discovered 5 subtypes of liver disease, each with unique risks for heart disease, liver failure, and cancer. The study, published in Nature Communications, used genetic sequencing and clinical data to define distinct subtypes of metabolic dysfunction-associated steatotic liver disease.
The Lancet Haematology series examines how clinicians can better identify and track treatment effects on patients during and after blood cancer treatment. Digital tools, such as symptom-reporting apps and artificial intelligence, could support changes in care, but must be accurate and equitable.
Scientists have identified a microbiome signaling system that controls intestinal movement, revealing a potential new direction for treating constipation-predominant irritable bowel syndrome. The discovery points to restoring combinations of microbial signals to restore normal function.
Mayo Clinic joins a consortium to develop affordable, scalable gene-editing therapies for children with rare inherited immune disorders. Researchers will use CRISPR-based technologies to repair disease-causing errors in blood-forming stem cells.
Researchers estimated cancer risk in patients with pancreatic cysts with worrisome or high-risk features, finding that risk increased with the number of worrisome features. The study suggests that regular surveillance may be an appropriate approach for some patients rather than immediate surgery.
The AI model, developed by Mayo Clinic researchers, can identify patients with left ventricular outflow tract obstruction from routine ultrasound videos without relying on specialized Doppler imaging. This technology could help clinicians flag patients with hypertrophic cardiomyopathy who may need additional testing, particularly in se...
Researchers developed an experimental drug using AI to target a 'undruggable' protein in pancreatic cancer, slowing tumor growth and improving survival rates. The study demonstrates the potential for AI-assisted discovery of new cancer treatments.
A Mayo Clinic study highlights the benefits of animal-assisted treatment in stroke rehabilitation, showing increased patient engagement and improved rehabilitation outcomes. Therapy animals support patients with limited motivation, reduced energy and lack of companionship.
Researchers discovered a protein called TRAILshort that suppresses T-cell activity and reduces the effectiveness of CAR-T cell therapy in cancer patients. Elevated levels of TRAILshort were found in various cancers, infectious diseases, and autoimmune disorders.
The collaboration enables researchers and innovators to develop, validate, and scale AI-enabled solutions across a broader representation of patient populations. This global health data network, called Mayo Clinic Platform_Connect, includes eight members and spans seven countries across three continents.
Researchers identify a previously unknown mechanism linking dysfunctional mitochondria and epigenetic machinery to chronic inflammation in aging cells. The discovery reveals how senescent cells drive inflammation by switching on inflammatory genes through metabolic signals from mitochondria.
Researchers develop SenMayo gene set to identify senescent cells across different tissues and experimental models. Several studies evaluate approaches to reduce the burden or harmful effects of senescent cells in preclinical models.
A new immunotherapy treatment has been shown to be effective in treating high-risk bladder cancer, allowing many patients to keep their bladder instead of having it surgically removed. The treatment, called cretostimogene grenadenorepvec, produced a complete response in 75% of patients, with most side effects being mild and temporary.
A Mayo Clinic study found that bringing clinical trial activities directly to patients can increase participation among rural and underserved communities. The decentralized program expanded access to research, increasing enrollment from 16.6% to 24.9% in rural communities and 12.5% to 17.4% among underserved racial and ethnic populations.
Researchers identified a distinct biological subtype of obesity that responds well to GLP-1-based medications like tirzepatide. Patients in this group lost an average of 21.5% of their body weight after six months of treatment.
A Mayo Clinic-led study found that continuing maintenance therapy beyond two years did not improve overall survival for patients with standard-risk multiple myeloma. The findings suggest that treatment duration can be safely tailored, reducing treatment burden and costs.
Researchers have validated a genetic scoring tool that can identify patients with idiopathic pulmonary fibrosis and predict clinical outcomes. The tool, which combines the effects of over 60,000 DNA variants, shows promise in distinguishing the disease from other forms of interstitial lung disease.
A new Mayo Clinic study shows that integrating telomere length evaluation and genetic testing into pulmonary care can significantly change how physicians diagnose and treat pulmonary fibrosis. Nearly 1 in 5 patients had a disease-causing genetic variant, leading to changes in clinical care for more than half of patients.
Researchers created a detailed map of the pulvinar, a deep brain region that could help doctors precisely target brain stimulation therapies for people with drug-resistant epilepsy. The study reveals that brain regions separated by only a few millimeters connect to entirely different brain networks.
Researchers found that patients who received tranexamic acid during liver surgery were three times less likely to develop post-hepatectomy liver failure than those who received a placebo. The study suggests targeting the body's fibrinolytic system may support liver regeneration and reduce liver failure risk.
Mayo Clinic researchers have identified a previously hidden step in the immune system's preparation to fight cancer, suggesting that the thymus plays a crucial role in training T cells before they enter circulation. This discovery could lead to more effective and longer-lasting cancer immunotherapies.
Mayo Clinic researchers have discovered the molecular structure of protein kinase C beta (PKCβ), a key protein linked to cancer and neurological diseases. The findings provide a promising target for developing more precise therapies for these conditions, including breast cancer and Alzheimer's disease.
Researchers have identified a previously unrecognized way the kidneys regulate water balance, which could lead to improved treatments for polycystic kidney disease. The discovery reveals an alternative mechanism that operates independently of the hormone vasopressin.
Researchers mapped individual cell genetic footprints to understand tumor behavior, identifying distinct immune cell states linked to disease aggressiveness and patient outcomes. The study aims to refine treatment decisions and develop noninvasive biomarkers for monitoring patients.
Researchers used tissue samples, pathology images, and clinical data from 672 patients to train AI models to classify meningioma subtypes and predict recurrence risk. The findings suggest that AI can help clinicians obtain more detailed tumor information without requiring advanced genetic testing.
A new proactive treatment protocol, PACT, combines medication and frequent follow-up to prevent alcohol relapse after liver transplant. Researchers found a 0% heavy alcohol relapse rate among patients who followed the protocol, compared to a historical rate of approximately 25%.
The collaboration aims to expand access to Mayo Clinic's knowledge and integrated model of care, using advanced AI capabilities to support earlier diagnoses, personalized treatment decisions, and better patient outcomes. The frontier AI model will be owned by Mayo Clinic and made available through Microsoft Azure Foundry APIs.
A recent study found that hormone therapy use among US women has steadily declined from 4.4% in 2007 to 1.7% in 2023, despite its proven benefits for symptom relief and quality of life. The majority of women who could benefit from hormone therapy are not receiving it due to misconceptions about risks and limited training among clinicians.
Researchers will present over 30 studies on precision oncology, early cancer detection and AI-powered personalized care. Featured topics include biomarker-driven treatments for bladder and lung cancers, new approaches for triple-negative breast cancer and AI-enabled analysis of tumor microenvironment in colon cancer.
A new Mayo Clinic study sequenced the genomes of 484 healthy adults, finding that 13% carried a serious genomic risk. The study highlights the challenges of integrating genomic findings into routine care and positions predictive genomic screening as a clinical opportunity.
Researchers identified ST8Sia6, an immune-regulating molecule, as a potential explanation for treatment-resistant IBD. The study found that the absence of ST8Sia6 led to increased inflammation in preclinical models.
Dr. Gianrico Farrugia will complete his tenure as Mayo Clinic President and CEO in December, leaving a legacy of strategic advancement and innovation. The institution has accelerated disease cures, connected people with data, and transformed healthcare through its AI-enabled care transformation platform.
The study identifies nine distinct cellular neighborhoods in the tumor microenvironment, each associated with survival and immunotherapy response outcomes. The blood-based liquid biopsy test could guide treatment decisions for multiple cancer types and treatments.
A study published in JHLT Open found that remote patient monitoring can detect early health changes and support care decisions for lung transplant recipients. The system generated nearly 470 alerts, with most prompting changes in care, such as clinic visits or medication adjustments.
The Mayo Clinic AI model detects pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis, identifying subtle signs of disease. The model identified 73% of prediagnostic cancers at a median of about 16 months before diagnosis.